A practical reference on anti-doping analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
BMR (Males) in Kcals/day = 88.36 + 13.40 (weight in kg) + 4.8 (height in cm) – 5.68 (age in years) BMR (Females) in Kcals/day = 447.59 + 9.25 (weight in kg) + 3.10 (height in cm) – 4.33 (age in years) The Mifflin St. Jeor Equation is as follows:
=== Cation exchange === Cation exchange sorbents are derivatized with functional groups that interact and retain positively charged cations, such as bases. Strong cation exchange sorbents contain aliphatic sulfonic acid groups that are always negatively charged in aqueous solution, and weak cation exchange sorbents contain aliphatic carboxylic acids, which are charged when the pH is above about 5. Strong cation exchange sorbents are useful because any strongly basic impurities in the sample will bind to the sorbent and usually will not be eluted with the analyte of interest; to recover a strong base a weak cation exchange cartridge should be used. To elute the analyte from either the strong or weak sorbent, the stationary phase is washed with a solvent that neutralizes ionic interaction between the analyte and the stationary phase.
Amino acid sequence: Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Val-Ile-... Plasma angiotensinogen levels are increased by plasma corticosteroid, estrogen, thyroid hormone, and angiotensin II levels. In mice with a full body deficit of angiotensinogen, the effects observed were low newborn survival rate, stunted body weight gain, stunted growth, and abnormal renal development.
Tofisopam has also appeared in Washington State’s equine drug regulations. Washington State regulatory documents list ‘’‘Grandaxain’’’ and ‘’‘Seriel’’’ and as a Class 2 substance within equine medicine. Tofisopam has been shown to act as an inhibitor of the liver enzyme CYP3A4, and some researches suspect that this could cause dangerous drug interactions with other medications metabolised by this enzyme, although the clinical significance of these findings remains unclear.
=== M–Mey === Ida Maclean (1877–1944). British biochemist at the Lister Institute of Preventive Medicine, known work on fatty acids in animals and fat synthesis. John Macleod FRS (1876–1935). British biochemist and physiologist at the University of Toronto, discoverer of insulin. Nobel Prize in Physiology or Medicine (1923). Thaddeus Mann FRS (1908–1993). Ukrainian-British biochemist at the University of Cambridge, who worked on reproductive biology. Bengt Mannervik (b. 1943). Swedish biochemist at Stockholm University known for work on enzymes related to glutathione metabolism. Emanuel Margoliash (1920–2008). Israeli-American biochemist at Northwestern University, known for research on cytochrome c sequences, which formed the starting point for studies of protein evolution. Member Natl. Acad. Sci. USA. Vincent Massey FRS (1926–2002). Australian biochemist and enzymologist at the University of Michigan, best known for studies of flavoenzymes. Member Natl. Acad. Sci. USA. Elmer Verner McCollum (1879–1967). American biochemist at Johns Hopkins University, who discovered Vitamins A and D, and their benefits. Member Natl. Acad. Sci. USA. Harden M. McConnell (1927–2014). American biochemist at Stanford known for the technique of spin-labels, whereby electron and nuclear magnetic resonance can be used to study the structure and kinetics of proteins. Member Natl. Acad. Sci. USA. William D. McElroy (1917–1999). American biochemist and science administrator at University of California San Diego. Member Natl. Acad. Sci. USA. Enrique Meléndez-Hevia (born 1946).
Sources: en.wikipedia.org
The twenty-foot equivalent unit is the volume of the smallest standard shipping container. It is equivalent to 1,172 cubic feet (33.2 m3). Larger intermodal containers are commonly described in multiples of TEU, as are container ship capacities.
Other impacts on exposure in utero PFOA exposure on thyroid function has also been a topic of concern, and has found to negatively impact thyroid stimulating hormone even at low levels when exposed during fetal development. PFOA is also shown to have obesogenic effects, and an experimental study found a positive correlation to low-dose prenatal exposure of PFOA and prevalence of overweight and high waist circumference in females at age 20. A correlation between in utero PFOA exposure and mental performance has yet to be established, as many studies have resulted in insignificant results. For example, a study conducted near Parkersburg, West Virginia did not find a significant association between in utero PFOA exposure and performance of math skills or reading performance in children ages 6 to 12 living in the PFOA-contaminated water district. Based on a cohort study conducted in the Mid-Ohio Valley, no clear association was found between prenatal exposure to PFOA and birth defects, although a possible association with brain defects was observed and requires further research and assessment. Extrapolated epidemiological data suggests a slight association between PFOA exposure and low birth weight. This was consistent based on blood levels of PFOA metabolites regardless of the geographic residence of subjects. Generally, the findings among human fetuses exposed to the chemical were considerably less drastic than what was seen in mice studies. Because of this, studies linking exposure to low birth weight can be considered inconclusive.
== External links == XB1: The First Conference on Xenobiology Archived 2019-04-03 at the Wayback Machine May 6–8, 2014. Genoa, Italy. XB2: The Second Conference on Xenobiology May 24–26, 2016. Berlin, Germany.
The North American Aviation P-51 Mustang is an American long-range, single-seat fighter and fighter-bomber used during World War II and the Korean War, among other conflicts. The Mustang was designed in 1940 by a team headed by James H. Kindelberger of North American Aviation (NAA) in response to a request from the British Purchasing Commission. The commission approached NAA to build Curtiss P-40 fighters under license for the Royal Air Force (RAF). Rather than build an old design from another company, NAA proposed the design and production of a more modern fighter. The prototype NA-73X airframe was completed on 9 September 1940, 102 days after contract signing, achieving its first flight on 26 October. The Mustang was designed to use the Allison V-1710 engine without an export-sensitive turbocharger or a multi-stage supercharger, resulting in limited high-altitude performance. The aircraft was first flown operationally by the RAF as a tactical-reconnaissance aircraft and fighter-bomber (Mustang Mk I). In mid 1942, a development project known as the Rolls-Royce Mustang X, replaced the Allison engine with a Rolls-Royce Merlin 65 two-stage inter-cooled supercharged engine. During testing at Rolls-Royce's airfield at Hucknall in England, it was clear the engine dramatically improved the aircraft's performance at altitudes above 15,000 ft (4,600 m) without sacrificing range.
=== Real-time monitoring === Since indoor air pollutants can adversely affect human health, it is important to have real-time indoor air quality assessment/monitoring system that can help not only in the improvement of indoor air quality but also help in detection of leaks and spills in a work environment. It can also boost energy efficiency of buildings by providing real-time feedback to the heating, ventilation, and air conditioning (HVAC) system(s). Additionally, there have been enough studies that highlight the correlation between poor indoor air quality and loss of performance and productivity of workers in an office setting. Combining Internet of Things (IoT) technology with real-time IAQ monitoring systems has gained popularity as interventions can be done based on the real-time sensor data, assissting in IAQ improvement.
Sources: en.wikipedia.org
== Education == McAlpine was awarded an honours bachelor's degree at Western University where she won a gold medal in zoology. She received a master's degree from the University of Toronto in 1966. Her thesis was called An assessment of the creatine kinase test in the detection of carriers of Duchenne muscular dystrophy. She went on to complete a PhD at University College London in 1970 with a thesis entitled Studies on the genetic variation of phosphoglucomutase in man. McAlpine was mentored and supervised by women in her field throughout her education. Her undergraduate work was performed under Helen Battle, and Margaret Thompson was her advisor in Toronto. Her PhD supervisor was Harry Harris.
The VIP gets 200 armor and has 150% movement speed; they also have a unique skin for identification purposes. Formerly, there was a fourth objective called Escape. In this scenario, the terrorist team had to "escape" to a designated escape point while the Counter-Terrorist team tried to kill them. When half of the team has managed to escape, the Terrorists win the round. Following each of the eight rounds of play, the two sides will trade roles. If one team eliminates the other, either team can win the scenario. A heads-up display (HUD) shows information to assist players during gameplay. The action indicator in the top right displays the names of players who are killed and the weapon used. The radar, or mini-map, shows the positions of teammates and other relevant map details. The HUD displays the player's health, armor, ammunition, and money as well as the round timer. On the left side, icons indicate important locations such as hostage rescue areas, VIP escape points, buy zones, and bomb sites, and in bomb defusal maps, it shows whether the player is carrying the C4 bomb or a defuse kit. There are three categories of weapons: melee (knife), secondary (handguns), and primary (rifles, shotguns, machine guns, and submachine guns). Players are only allowed to carry one weapon of each category at a time. There is a separate category for equipment like defusing kits and hand grenades which do not have the same carry limits.
In terms of the effects of progestogens on sex drive, one study assessed the use of dydrogesterone to improve sexual desire in transgender women and found no benefit. Another study likewise found that oral progesterone did not improve sexual function in cisgender women. Progestogens can have adverse effects. Oral progesterone has inhibitory neurosteroid effects and can produce side effects such as sedation, mood changes, and alcohol-like effects. Many progestins have off-target activity, such as androgenic, antiandrogenic, glucocorticoid, and antimineralocorticoid activity, and these activities likewise can contribute unwanted side effects. Furthermore, the addition of a progestin to estrogen therapy has been found to increase the risk of blood clots, cardiovascular disease (e.g., coronary heart disease and stroke), and breast cancer compared to estrogen therapy alone in postmenopausal women. Although it is unknown if these health risks of progestins occur in transgender women similarly, it cannot be ruled out that they do. High-dose progestins increase the risk of benign brain tumors including prolactinomas and meningiomas as well. Because of their potential detrimental effects and lack of supported benefits, some researchers have argued that, aside from the purpose of testosterone suppression, progestogens should not generally be used or advocated in transgender women or should only be used for a limited duration (e.g., 2–3 years).
still holds, the surface energy (γ) predicted by Griffith's theory is usually unrealistically high. A group working under G. R. Irwin at the U.S. Naval Research Laboratory (NRL) during World War II realized that plasticity must play a significant role in the fracture of ductile materials. In ductile materials (and even in materials that appear to be brittle), a plastic zone develops at the tip of the crack. As the applied load increases, the plastic zone increases in size until the crack grows and the elastically strained material behind the crack tip unloads. The plastic loading and unloading cycle near the crack tip leads to the dissipation of energy as heat. Hence, a dissipative term has to be added to the energy balance relation devised by Griffith for brittle materials. In physical terms, additional energy is needed for crack growth in ductile materials as compared to brittle materials. Irwin's strategy was to partition the energy into two parts:
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.